Risk model based on minichromosome maintenance 2 using objective assessment for predicting survival of neuroblastoma
Author:
Zeng Liang,
Liu Xiao-Yun,
Miao Lei,
Chen Kai,
Xu Hui,
Qin Liang-Jun,
Li Meng,
Liu Kai,
Feng JiahaoORCID,
Wang Hai-Yun
Subject
Multidisciplinary
Reference34 articles.
1. Neuroblastoma;Maris;Lancet,2007
2. Neuroblastoma;Matthay;Nat. Rev. Dis. Prim.,2016
3. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial;Ladenstein;Lancet Oncol.,2017
4. Long-term results of the combination of the N7 induction chemotherapy and the busulfan-melphalan high dose chemotherapy;Valteau-Couanet;Pediatr. Blood Cancer,2014
5. The DNA replication regulator MCM6: an emerging cancer biomarker and target;Zeng;Clin. Chim. Acta,2021